Efficacy of antiviral treatment of chronic hepatitis C in patients with HCV/HIV coinfection in the comparative aspect
AbstractThe study included 77 patients with HCV/HIV coinfection: the first group (n=59) who received pegylated interferon alpha 2a (Peg-IFN-a2a) (at a dose of 180 mcg/week) and ribavirin (dose determined in depending on the HCV genotype) for 48 weeks, and the second consisted of 18 patients who were prescribed standard IFN-alpha 2b (St-IFN-a2b) 5 million IU with a daily regimen of administration of the first 24 weeks, then every other day up to 48 weeks in combination with ribavirin (10-15 mg/ kg/day).Efficiency of therapy with St-IFN-a2b and Peg-IFN-a2a in combination with ribavirin in HCV/HIV coinfection is comparabLe to the high frequency of achieving SVR in patients with CC genotype rs12979860 (76 and 78%) and the reLapse rate was 9.8 and 11.1% in the respective groups.
Keywords:HCV-infection, HCV/HIV ^infection, interferon-alpha
Infectious Diseases: News, Opinions, Training. 2017; (4): 51-56. DOI: 10.24411/2305-3496-2017-00068